science
The Real‑World Effectiveness of Aumolertinib for Rare EGFR Mutations in Lung Cancer
May 4, 2026
Aumolertinib, a newer drug that targets the epidermal growth factor receptor (EGFR), has been tested in two hospitals on patients with a rare form of lung cancer. The cancer cells carry uncommon deletions in exon 19 of the EGFR gene, a pattern that often makes standard treatments less reliable. R
